Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1569912 Dose-Finding as Adjunctive Therapy in Major Depressive Disorder
2023-507942-10-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing BI 1569912 + SSRI/SNRI with Placebo + SSRI/SNRI (2 arms). Primary endpoint: Change from baseline in MADRS total score at Week 6. Started Jul 2024; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2023-507942-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507942-10-00.